Targeting MET: Why, where and how?

Elena Ghiso, Silvia Giordano

Research output: Contribution to journalArticlepeer-review


Despite the initial skepticism, targeted therapies represent a new perspective in the treatment of cancer. Tyrosine kinases, and in particular receptor tyrosine kinases (RTKs), are considered ideal targets for this type of therapy. MET, the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), has recently become a very interesting and studied target in oncology. In this review we discuss firstly 'why' the MET/HGF pathway can be considered a target in human tumors; secondly 'where' MET/HGF inhibition can be useful in cancer treatment and finally 'how' MET and HGF can be inhibited using either monoclonal antibodies or tyrosine kinase inhibitors. We also highlight some questions in the anti-MET/HGF targeted therapy field that are still waiting for an answer.

Original languageEnglish
Pages (from-to)511-518
Number of pages8
JournalCurrent Opinion in Pharmacology
Issue number4
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Targeting MET: Why, where and how?'. Together they form a unique fingerprint.

Cite this